Understanding how too much EWS/FLI1 protein affects Ewing sarcoma cells
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
This study is looking at how high levels of a specific protein affect Ewing sarcoma, a type of bone cancer that mostly affects kids, to find out how we can help make cancer cells die off and discover new ways to treat this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11085216 on NIH RePORTER |
What this research studies
This research investigates the effects of excessive levels of the EWS/FLI1 fusion protein in Ewing sarcoma, a common bone cancer in children. The study aims to uncover the mechanisms that lead to cell death when these protein levels are too high, as well as how they are regulated within a safe range. By using advanced techniques like CRISPR and shRNA, researchers will explore how manipulating these protein levels can impact cancer cell survival. The findings could provide insights into new treatment strategies for Ewing sarcoma and potentially other related cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with Ewing sarcoma, particularly those aged 0-11 years.
Not a fit: Patients with other types of cancers or those who do not have Ewing sarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that improve outcomes for children with Ewing sarcoma.
How similar studies have performed: While the specific approach of studying EWS/FLI1 overdose is relatively novel, similar research on EWS fusion proteins has shown promising results in understanding cancer biology.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Stegmaier, Kimberly — Dana-Farber Cancer Inst
- Study coordinator: Stegmaier, Kimberly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.